Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. - Wikidata - wikimedia - TriplyDB

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

http://www.wikidata.org/entity/Q45814967

about

RANK-RANKL signalling in cancer Bone Metastasis from Renal Cell Carcinoma Bone metastases: When and how lung cancer interacts with bone Targeting RANKL in metastasis Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro Genetic polymorphism of the OPG gene associated with breast cancer.RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran.C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.RANK/RANKL pathway in cancer: Biological activity beyond bone?Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.ER and PR signaling nodes during mammary gland development.CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells Role of sympathetic nerves in the establishment of metastatic breast cancer cells in bone Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.Effects of RANKL-Targeted Therapy in Immunity and Cancer.RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src.RANKL inhibition: a promising novel strategy for breast cancer treatment.Denosumab for treatment of breast cancer bone metastases and beyond.Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.Premetastatic niche: ready for new therapeutic interventions?Role of nuclear factor-ĸB in breast and colorectal cancer.Targeting RANKL in breast cancer: bone metastasis and beyond.Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.Cell migration on planar and three-dimensional matrices: a hydrogel-based perspective.The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors.Emerging drugs for the treatment of bone metastasis.Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.

P2860

Q26747442-A5FE9E0E-33BB-4627-A042-4415B7860A4F Q26747493-2668C6EE-5C43-4A2E-BF72-498662116B51 Q26823287-2386EE67-4F7E-45DC-A991-334220607E5F Q26849690-0507A28D-E39E-4775-9D24-01908112FC52 Q26863493-D652B5B9-3165-4410-8AB2-DBB97A74E4C1 Q27006383-C6CEE06A-BCA2-4FFD-8FCD-D92377B9A7BD Q28740575-FE888986-9EF4-49BA-81B1-255558F70C39 Q30419245-CCDBC37E-E6EB-46C2-8D34-953F5EA7CE35 Q30534404-F44480A9-AB81-489D-9D84-44399FA2F691 Q34209272-A167EE29-8BB7-4777-9A62-FB239EB027CE Q34277337-BB865FC7-BAE4-4B7A-98FC-1A07584AEB80 Q34344554-C393265A-8646-4329-A723-F1DD543FE33E Q34402141-5FC61608-A752-4FE4-AD97-1FBB7350C083 Q34939979-B66BE97E-C23F-4F49-93AC-E32FF3B37AAF Q35133898-4C818DAE-2F88-49EB-AF50-6D36D760ADC3 Q35995710-916D43E6-1D00-4064-9817-7D4A4497247C Q36356112-34AAF05E-D692-4F0E-BF73-FA48A93473C2 Q36491425-7E36EE6B-CC00-4959-878D-ADA0EB56CF6B Q36759374-152C63CA-A4D9-403B-A7C5-20DE7C4EE433 Q36848283-6223959B-D998-4AD9-9F2E-4D0E47EB5C59 Q36924384-CC9FCAF3-2B5E-4085-9ABD-6B107F2BBF03 Q37295330-A87E859D-D167-43FC-BF06-C1068524CEDE Q37337499-613962CB-AD18-4A38-AAB5-75D80390B69C Q37356654-6C071FF9-C782-4581-90D7-07262CA78C1D Q37441693-E686DB3E-66DB-4790-9EA9-9EA5365E9645 Q37582762-01299D27-A680-46F8-90D7-C05EF6B8E286 Q37865171-3D09318E-D1DE-4DAE-8A9A-57F4CC6D8EEF Q37986124-8B8A4A6C-C0C6-4CE8-A963-A50B1A87E153 Q37990849-1FA2354F-EDAA-4077-9FD5-B86B9BB0F009 Q37996455-1F3C7DBB-171F-439E-992F-60060762A6CB Q38041500-9D6A1E36-58A6-4C3C-882F-132C404BEBC0 Q38081245-259CB105-C4F9-4687-95FA-3559A43E0EE6 Q38155200-CF490F1A-1F3D-4AF9-92B3-C1B0B4ADF4E1 Q38228128-20E8AA03-B8A8-409C-8BC3-022909BDE627 Q38524842-A973C1B6-9705-4BD2-8771-41744641E14F Q38538263-F1FBDB82-E064-4C07-9183-8F5B1BC4289B Q38747404-61C37BDC-FB20-4775-8D2E-1695276E4908 Q38956445-183A7BDB-0D3A-4940-A3F2-2BA023112449 Q39000185-05A5D41F-B335-40D1-B513-DE4AB43C0589 Q39010800-3BCBC2EA-BF7A-403C-922C-CDD194C72586

P2860

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

http://www.wikidata.org/entity/Q45814967

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Expression pattern of receptor ...... s and related bone metastases.

@en

Expression pattern of receptor activator of NFκB

@nl

type

label

Expression pattern of receptor ...... s and related bone metastases.

@en

Expression pattern of receptor activator of NFκB

@nl

prefLabel

Expression pattern of receptor ...... s and related bone metastases.

@en

Expression pattern of receptor activator of NFκB

@nl

P1433

Q45814967-65E457A5-4A72-4579-AB80-4EE2F178EA26

P1476

Q45814967-CE025872-2B6C-4F42-AB85-B1ED82EB113E

P2093

Q45814967-14ED243C-7BF9-46B6-BC7C-CFFD3B678334

Q45814967-17B19616-C8F8-43C8-B982-3908CD5B9562

Q45814967-32EDB7A3-847E-4BC6-BFC2-8AF14046DBB5

Q45814967-33382F3F-78B2-43A2-8301-D510D74894BB

Q45814967-34D8E194-25AE-4BFB-A327-E9DCCCCE6224

Q45814967-674EE6F6-9AEF-4673-80F2-C077DD328788

Q45814967-6F097C23-AC73-4863-9D92-9EA1303DE442

Q45814967-7E896486-23F4-418E-BE97-59D3C00993DF

Q45814967-7EBC5258-09AC-433B-B2B7-4D1CFB1BF236

Q45814967-A2401810-61DB-45F7-AACE-265F78D26C55

P2860

Q45814967-01632260-1C5B-4F09-9D63-69241FD39AC9

Q45814967-5D102F75-28DB-4798-BB8D-124FFEE164D9

Q45814967-7450461F-3B5C-453B-BB34-8E1740355B85

Q45814967-774400EA-A3B2-4A33-BA38-8D9A89E41745

Q45814967-8DA7C635-B711-4CB6-96A0-DD67155B0F70

Q45814967-97685F83-188B-4EBE-998B-84CF527924B4

Q45814967-AB5FCD41-1CA0-4492-8260-F8D4B8F37BEF

Q45814967-C1B1C2F8-8A5A-4AC0-A3F4-480BD4210D0D

Q45814967-C4160DAF-3FC0-4F35-8E96-21BB851B8D1E

Q45814967-D0148087-570A-4F90-BCE8-AE60C370592A

P304

Q45814967-50DF8FF7-42F7-4DA0-AE21-10CD468C3847

P31

Q45814967-1AE8D4C5-66A2-4B90-A28B-7B130DF06D3C

P356

Q45814967-B2749797-1B0A-4E0D-9BA0-80573D3C4684

P433

Q45814967-3AC49B26-BEDC-44A7-8225-7C9D447CC9F3

P478

Q45814967-93FD9493-FACC-4AE9-BAD5-A34314D0A1FF

P50

Q45814967-08C10CA8-4B6E-4A19-BE90-10350561DCE3

Q45814967-25243A13-ABEE-462C-93A3-2BCC82E0A9C6

Q45814967-31B10630-D31B-4CBD-8ACA-66F3E0F50586

Q45814967-3E0948AC-0411-4F6F-BC61-CEB0555A6289

Q45814967-70628A7A-A09E-4022-8F5F-F7DA0DAA1D0F

Q45814967-7A168EF0-72D1-4D07-8490-79837FDC59CF

Q45814967-8037EC8D-3F73-437F-B175-E95405A4E2DE

Q45814967-99841940-DBD2-4AC9-94DC-6C84AB5F2712

Q45814967-A3BBAC9D-132D-4648-9779-E2C6C5D1439C

Q45814967-DB25F277-720D-48B3-B2A4-D85BF07C238B

P577

Q45814967-E5AB9FA1-D29D-40A0-8B21-E041EE038C50

P5875

Q45814967-E887760D-A653-4A56-9ADB-F3305567A026

P698

Q45814967-C2B9D563-35E6-4955-BAC4-21B03421D690

P356

P1433

Journal of Cellular Physiology

P1476

Expression pattern of receptor ...... s and related bone metastases.

@en

P2093

Alessandro Del Conte

http://www.w3.org/2001/XMLSchema#string

Alfredo Berruti

http://www.w3.org/2001/XMLSchema#string

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Donatella Grasso

http://www.w3.org/2001/XMLSchema#string

Gaia Schiavon

http://www.w3.org/2001/XMLSchema#string

Laura Godio

http://www.w3.org/2001/XMLSchema#string

Maria Elisabetta Fratto

http://www.w3.org/2001/XMLSchema#string

Mauro Papotti

http://www.w3.org/2001/XMLSchema#string

Nicola Papapietro

http://www.w3.org/2001/XMLSchema#string

Roberto Sabbatini

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.

Functions of RANKL/RANK/OPG in bone modeling and remodeling.

Regulation of cancer cell migration and bone metastasis by RANKL.

Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells.

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

P304

780-784

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCP.22402

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

226

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Giuseppe Tonini

Vincenzo Denaro

Francesco Pantano

Andrea Onetti Muda

Giuseppe Perrone

Chiara Della Pepa

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46382988

http://www.w3.org/2001/XMLSchema#string

P698

20857484

http://www.w3.org/2001/XMLSchema#string